The Addictive Disorders drugs in development market research report provides comprehensive information on the therapeutics under development for Addictive Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Addictive Disorders. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Addictive Disorders and features dormant and discontinued products.
GlobalData tracks 19 drugs in development for Addictive Disorders by 18 companies/universities/institutes. The top development phase for Addictive Disorders is preclinical with 11 drugs in that stage. The Addictive Disorders pipeline has 17 drugs in development by companies and two by universities/ institutes. Some of the companies in the Addictive Disorders pipeline products market are: Mydecine Innovations Group, AWAKN Life Sciences and Delix Therapeutics.
The key targets in the Addictive Disorders pipeline products market include 5-Hydroxytryptamine Receptor 2A, 5-Hydroxytryptamine Receptor 2C, and 5-Hydroxytryptamine Receptor 1A.
The key mechanisms of action in the Addictive Disorders pipeline product include 5-Hydroxytryptamine Receptor 2A Agonist with six drugs in Phase I. The Addictive Disorders pipeline products include four routes of administration with the top ROA being Oral and two key molecule types in the Addictive Disorders pipeline products market including Small Molecule, and Recombinant Protein.
Addictive Disorders overview
Addictive disorders, such as substance abuse and dependence, are common disorders that involve the overuse of alcohol and/or drugs. Addiction develops over time and is a chronic and relapsing illness. Addictive disorders are caused by multiple factors, including genetic vulnerability, environmental stressors, social pressures, individual personality characteristics and psychiatric problems.
For a complete picture of Addictive Disorders’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
